Lansoprazole
Zollinger-Ellison Syndrome, Curling Ulcer, maintenance of healing Erosive esophagitis + 9 more
Treatment
5 FDA approvals
5 Active Studies for Lansoprazole
Treatment for
Zollinger-Ellison Syndrome
What is Lansoprazole
Lansoprazole
The Generic name of this drug
Treatment Summary
Dexlansoprazole is a proton pump inhibitor (PPI) used to manage symptoms of gastroesophageal reflux disease (GERD) and erosive esophagitis. It is a newer generation PPI that is released in two phases in the body, resulting in two peaks of concentrations in the blood. Dexlansoprazole works by targeting an enzyme responsible for producing stomach acid, which reduces the amount of acid in the stomach. It is generally well-tolerated and can be used for long periods of time, although it can have some adverse effects such as increased risk of bacterial infections
Prevacid
is the brand name
Lansoprazole Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prevacid
Lansoprazole
1995
326
Approved as Treatment by the FDA
Lansoprazole, otherwise known as Prevacid, is approved by the FDA for 5 uses like Duodenal Ulcer and Zollinger-Ellison Syndrome .
Duodenal Ulcer
Used to treat Duodenal Ulcer in combination with Amoxicillin
Zollinger-Ellison Syndrome
Helps manage Zollinger-Ellison Syndrome
hypersecretory conditions
Helps manage hypersecretory conditions
Helicobacter Pylori Infection
Used to treat Helicobacter Pylori Infection in combination with Amoxicillin
Curling Ulcer
Used to treat Duodenal Ulcer in combination with Amoxicillin
Effectiveness
How Lansoprazole Affects Patients
Dexlansoprazole is a type of drug that reduces the amount of acid produced in the stomach. It works by blocking the enzyme (H+, K+)-ATPase, which is found on the surface of cells in the stomach lining. This prevents acid from being released.
How Lansoprazole works in the body
Dexlansoprazole works to decrease the amount of acid in your stomach. It does this by blocking an enzyme, H/K ATPase, which helps create hydrochloric acid. The drug is released into your system in two phases, first in the upper part of your small intestine, then further down. This helps the medication to be more effective. Dexlansoprazole helps reduce both regular and extra acid levels in the stomach.
When to interrupt dosage
The advised dosage of Lansoprazole is contingent upon the diagnosed condition, including healed erosive esophagitis, symptomatic non-erosive gastroesphageal reflux disease and Heartburn. The measure of dosage varies, as per the technique of administration (e.g. Capsule, delayed release or Tablet, orally disintegrating, delayed release) specified in the table beneath.
Condition
Dosage
Administration
Zollinger-Ellison Syndrome
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Curling Ulcer
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
maintenance of healing Erosive esophagitis
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Duodenal Ulcer
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
NSAID use
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
hypersecretory conditions
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Helicobacter Pylori Infection
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Erosive Esophagitis
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Ulcer Healing
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
A History of Gastric or Duodenal Ulcers
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Stomach Ulcer
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Gastroesophageal reflux disease
, 15.0 mg, 30.0 mg, 30.0 mg/mL
Kit, , Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Suspension, Suspension - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Kit - Oral, Capsule
Warnings
There are 20 known major drug interactions with Lansoprazole.
Common Lansoprazole Drug Interactions
Drug Name
Risk Level
Description
Albendazole
Major
The metabolism of Albendazole can be decreased when combined with Lansoprazole.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Lansoprazole.
Apixaban
Major
The metabolism of Apixaban can be decreased when combined with Lansoprazole.
Artemether
Major
The metabolism of Artemether can be decreased when combined with Lansoprazole.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Lansoprazole.
Lansoprazole Toxicity & Overdose Risk
The toxic dose of DEXILANT for mice, rats, and dogs is greater than 5,000mg/kg. Common side effects include diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and gas. High blood pressure has been reported in patients taking doses of DEXILANT twice a day. Research has shown that long-term use of the drug may lead to gastric ECL cell hyperplasia and ECL cell carcinoids in rats, as well as intestinal metaplasia of the gastric epithelium. There are no known effects on fertility or the reproductive system.
Lansoprazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Lansoprazole?
At present, there are 7 active trials examining the potential of Lansoprazole to alleviate Erosive Esophagitis, healed erosive esophagitis and symptomatic non-erosive gastroesphageal reflux disease.
Condition
Clinical Trials
Trial Phases
hypersecretory conditions
0 Actively Recruiting
A History of Gastric or Duodenal Ulcers
0 Actively Recruiting
Duodenal Ulcer
0 Actively Recruiting
maintenance of healing Erosive esophagitis
0 Actively Recruiting
Curling Ulcer
0 Actively Recruiting
NSAID use
0 Actively Recruiting
Ulcer Healing
1 Actively Recruiting
Not Applicable
Stomach Ulcer
0 Actively Recruiting
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Zollinger-Ellison Syndrome
0 Actively Recruiting
Gastroesophageal reflux disease
0 Actively Recruiting
Erosive Esophagitis
2 Actively Recruiting
Phase 2, Phase 3
Lansoprazole Reviews: What are patients saying about Lansoprazole?
5
Patient Review
5/6/2013
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
5
Patient Review
8/23/2014
Lansoprazole for Conditions of Excess Stomach Acid Secretion
5
Patient Review
3/20/2022
Lansoprazole for Medication Treatment for Healing Erosive Esophagitis
5
Patient Review
7/8/2014
Lansoprazole for Excessive Production of Stomach Acid
5
Patient Review
5/15/2015
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
5
Patient Review
5/14/2022
Lansoprazole for Increased Stomach Acid from Systemic Mastocytosis
4.7
Patient Review
9/17/2014
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
3.3
Patient Review
10/31/2013
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
3.3
Patient Review
12/16/2016
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
3
Patient Review
9/30/2017
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
2.7
Patient Review
5/26/2021
Lansoprazole for Indigestion
2.3
Patient Review
12/29/2013
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
2
Patient Review
4/19/2013
Lansoprazole for Heartburn
2
Patient Review
1/1/2015
Lansoprazole for Condition in which Stomach Acid is Pushed Into the Esophagus
1
Patient Review
5/30/2015
Lansoprazole for Heartburn
Patient Q&A Section about lansoprazole
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does lansoprazole cause weight gain?
"Lansoprazole does not create weight gain on its own, however it can lead to bloating or oedema. Oedema, caused by fluid retention, can lead to an increase in body weight, making one feel tired and heavy constantly. Another possible reason for weight gain after taking lansoprazole is that acidic foods are more likely to be eaten when the acid reflux subsides."
Answered by AI
What is lansoprazole used for?
"Lansoprazole is a medication that reduces the amount of acid produced by the stomach. It is used to treat conditions such as indigestion, heartburn, acid reflux, and gastroesophageal reflux disease (GORD). Lansoprazole can also be taken to prevent and treat stomach ulcers."
Answered by AI
How long can you safely take lansoprazole?
"You should not take non-prescription lansoprazole for more than 14 days or treat yourself with it more often than once every 4 months without talking to your doctor. You should also continue to take lansoprazole even if you feel well, and not stop taking prescription lansoprazole without talking to your doctor."
Answered by AI
Is lansoprazole stronger than omeprazole?
"There is no significant difference in the clinical effectiveness of omeprazole and lansoprazole for relieving symptoms of heartburn and regurgitation. However, omeprazole is more effective than lansoprazole in increasing intragastric pH."
Answered by AI